NCT00734305View on ClinicalTrials.gov

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

September 30, 2013

Conditions
Advanced Solid Tumors
Interventions
DRUG

MM-121

Dose escalation Frequency - once weekly

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

37232

The Vanderbilt-Ingram Cancer Center, Nashville

02115-6084

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Merrimack Pharmaceuticals

INDUSTRY